Dropping Plasma Erythritol Predicts Lower Heart Disease Risk After Weight Loss
A 2-year RCT finds that reducing plasma erythritol through dietary intervention cuts cardiovascular risk scores and improves dangerous lipid subtypes.
Summary
Erythritol is a sugar alcohol found naturally in the body and used as a sweetener, and elevated blood levels have recently been linked to heart attacks and strokes. In a 2-year randomized weight-loss trial involving over 800 overweight or obese adults, researchers measured plasma erythritol and related polyols at baseline and six months. Higher baseline erythritol predicted greater cardiovascular risk, but — crucially — participants whose erythritol levels dropped most over six months showed the largest long-term reductions in 10-year heart disease risk scores and in harmful VLDL and LDL particles containing apolipoprotein C-III. The other polyols tested did not show the same association. The findings suggest that tracking plasma erythritol could be a useful marker for monitoring cardiovascular improvement during weight-loss programs.
Detailed Summary
Erythritol has moved from obscurity to clinical spotlight after recent epidemiological data linked high circulating levels of this sugar alcohol to increased risk of major cardiovascular events. Yet whether bringing those levels down through lifestyle intervention actually improves cardiovascular risk has not been well characterized — until now.
Researchers analyzed data from the POUNDS Lost trial, a 2-year randomized weight-loss dietary intervention in adults with overweight or obesity. Plasma erythritol, arabitol/xylitol, and mannitol/sorbitol were measured at baseline (approximately 800 participants per polyol) and at six months, with changes tracked in roughly 665 participants per marker. The primary outcome was 10-year atherosclerotic cardiovascular disease (ASCVD) risk calculated via pooled cohort equations. Secondary outcomes included changes in cholesterol carried by lipoprotein subfractions with and without apolipoprotein C-III (apoC-III) over two years.
All three polyol families were associated with higher ASCVD risk at baseline. However, only erythritol showed a specific association between its decline and subsequent improvements: each standard-deviation reduction in plasma erythritol at six months corresponded to a statistically significant drop in ASCVD risk score both at six months and at two years. Those early erythritol declines also predicted long-term reductions in cholesterol carried by VLDL and LDL particles that contain apoC-III — a particularly atherogenic lipoprotein subfraction strongly tied to cardiovascular events.
The practical implication is two-fold. First, plasma erythritol may serve as a sensitive, modifiable biomarker of cardiovascular risk reduction during dietary weight-loss programs. Second, interventions that accelerate erythritol clearance — whether through diet composition, caloric restriction, or metabolic changes — may provide cardiovascular benefit beyond simple weight loss.
Caveats include the observational nature of the change analysis within an RCT, the lack of dietary erythritol intake data, and the fact that this summary is based on the abstract only, limiting access to full methodological detail and subgroup analyses.
Key Findings
- Higher baseline plasma erythritol independently predicted greater 10-year ASCVD risk in overweight and obese adults.
- Six-month declines in plasma erythritol — but not other polyols — were linked to significant reductions in cardiovascular risk scores.
- Early erythritol drops predicted long-term (2-year) reductions in apoC-III-containing VLDL and LDL, the most atherogenic lipid particles.
- Arabitol/xylitol and mannitol/sorbitol did not show the same specific cardiovascular benefit when reduced.
- Plasma erythritol may be a clinically useful biomarker for tracking cardiometabolic improvement during weight-loss interventions.
Methodology
Observational sub-analysis embedded within the POUNDS Lost 2-year randomized dietary weight-loss trial. Plasma polyols were measured at baseline and 6 months in approximately 800 adults with overweight or obesity; ASCVD risk and lipoprotein subfraction changes were assessed over 2 years using pooled cohort equations and apoC-III-stratified lipid panels.
Study Limitations
The change analysis is observational within an RCT, so causal inference is limited. Dietary erythritol intake was not quantified, making it impossible to separate endogenous production changes from altered consumption. This summary is based on the abstract only, as the full text was not accessible.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: